Algeta And Ablynx Join In Search For Targeted Cancer Radiotherapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Belgium-based Ablynx is pooling research with Algeta of Norway on an anti-cancer nanobody linked to the Norwegian biotech’s alpha-emitter thorium-227, in a move that could prove strategically important for both small companies.